REAL-AF Registry: Real-World Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies

REAL-AF Registry: Real-World Experience of Catheter Ablation for the Treatment of Symptomatic Paroxysmal and Persistent Atrial Fibrillation Using Novel Contact Force Technologies
Enrolling By Invitation
18-100 years
All
Phase N/A
500 participants needed
1 Location

Brief description of study

The REAL AF Registry is an observational, prospective, non-randomized registry designed to find out more about the outcomes for patients who receive an ablation as treatment for Paroxysmal Atrial Fibrillation (PAF) and Persistent (PsAF) Atrial Fibrillation. The registry aims to better understand real-world information for patients with this disorder. Eligible participants are referred by providers once they decide the patient will receive an ablation as treatment for PAF or PsAF.


 

Detailed description of study

Registry participation lasts about 1 year after the participant’s ablation. Any repeat ablations prior to the 12-month follow-up visit may mean that participation will exceed 12 months. This allows the registry team to collect data for 12 months after the date of the repeat ablation.

Patient assessments take place at the following time points: (1) pre-ablation or baseline, (2) procedure, (3) 10-12 weeks, (4) 6 months (monitor only) and (5) 1 year post ablation.

The registry team will collect specific information about participant’s medical history, the ablation procedure, and their follow up care. This includes any responses to AFib-specific patient questionnaires (AFEQT, AFSS, etc.) which the physician may collect.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Paroxysmal Atrial Fibrillation, Persistent Atrial Fibrillation
  • Age: Between 18 Years - 100 Years
  • Gender: All

Inclusion Criteria:

  • Symptomatic Paroxysmal (AF episode terminate spontaneously within 7 days) or Persistent (AF sustained beyond 7 days)
  • Able and willing to participate in baseline and follow up evaluations for the full length of the registry
  • Willing and able to provide informed consent

Exclusion Criteria:

  • Enrolled in an investigational drug or device clinical trial, or any trial that dictates the treatment plan
  • Long-standing persistent AF (AF longer than one year)
     
  • Having a repeat ablation, unless the first ablation procedure is also included in the registry
     

Updated on 11 Oct 2024. Study ID: 856321
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Office of Clinical Research